Integrated Software Solutions

  • Intellect Member
  • MSIA
  • HL7 Australia Member










OMNI-Lab smoothing the way to expanded newborn screening at GSTS Pathology

Press Release


Integrated Software Solutions Ltd, the specialist laboratory management software developer, today announces the latest implementation of its OMNI-Lab Newborn Screening management suite, this time at GSTS Pathology LLP, the unique and innovative joint venture between Guy�s and St Thomas� and King�s College Hospital NHS Foundation Trusts and Serco plc. OMNI-Lab software is at the heart of a system that facilitates the safe and efficient management of bloodspots, taken by heelprick for screening from thousands of newborn infants each year in the South East Thames region (approx. 60,000 live births p.a.). The screening either indicates that the infants are not suspected of having any of five serious diseases of infancy*, or alerts paediatricians to the need for further testing and/or possible treatment.


Prior to implementing OMNI-Lab, GSTS had been using a bespoke LIMS based on a custom-written and since unsupported MicrosoftTM Access 97TM database. Staff were concerned that the database was at increasing risk of data loss or corruption - unthinkable given the critically-important nature of the data being acquired and stored. In addition, the system was rapidly becoming obsolete in the face of new standards and was unable to interface with various laboratory analysers. So tenders were invited from several providers and Integrated Software Solutions, the developer of OMNI-Lab, was selected. Analie Booth, Service Delivery Manager � Biochemical Sciences at the time, stated: �We chose OMNI-Lab for its good electronic links, the fact that it future-proofed us and we liked its flexibility.�


Unlike previous customers for OMNI-Lab, who have usually opted for an off-the-peg solution, GSTS decided to get right under the skin of the system and build their own version from scratch. That meant several people learning how to write SQL and first they had to be trained by ISS. Analie explains: �We�ve got a system now that�s bespoke for us, but which is fully supported by ISS. We�ve built up the capability in house such that we�ve got experts on site and don�t have to wait for ISS to come up with the solutions to problems for us - we can start working on them ourselves, which is a massive bonus. Having said that, we�ve had a lot of support from the ISS guys both in Winchester, here in the UK and in Australia and that�s ongoing.� She added: �Although the implementation hasn�t been without teething problems,we�re getting there and we feel an awful lot safer than we did previously. We�ve also got interfaces to all our analysers, something we didn�t have before. In phase two of the project we�re looking to introduce messaging with child health and maternity units through an N3 secure data connection, allowing us to download patient details and populate our database automatically.�


GSTS is currently taking part in a pilot study for expanded newborn screening, so in addition to the usual five tests* they are also screening for five additional but rare conditions: Glutaric Aciduria Type 1 (GA1), Homocystinuria [pyridoxine unresponsive] (HCU), Isovaleric Acidemia (IVA), Maple Syrup Urine Disease (MSUD) and Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD. Analie comments: �As this is a pilot project we are not required to report the results of the extra tests back to the Child Health Records Department. At the moment we simply record the results and suppress them so they are not sent out to clinicians, but are available internally for statistical analysis.�


Analie observes that GSTS is constantly reviewing processes and that includes what is happening with OMNI-Lab so that, before manual checks are removed, the system is as safe as it possibly can be. She concludes: �OMNI-Lab has made us a lot safer overall and we have much more confidence in what�s happening with our processes. Phase two of the project will set the seal on OMNI-Lab�s effectiveness for us.�


Project Manager David Doran signed off for GSTS: �GSTS and Integrated Software Solutions (ISS) recently worked together to replace our existing newborn screening lab IT system with OMNI-Lab�s. The ISS Project Manager joined us in regular team meetings which brought about a very cohesive approach to meeting deadlines and making sure resources were available. We found ISS to have a �can-do� approach to our project and they were very supportive in getting the job done. Completing this project as �one team� ensured the project was delivered on time and under budget and will be an exemplar for our future projects.�


Alex Anderson, Managing Director of Integrated Software Solutions, noted: �What GSTS has done with OMNI-Lab illustrates perfectly just how versatile and therefore powerful it is � whether a lab wants to take an off-the-shelf solution straight from us or customise the suite to a high degree. It�s particularly exciting for us to be helping GSTS play its part in the Expanded Newborn Screening study, which is surely another ringing endorsement for OMNI-Lab in itself.�


* - The UK National Screening Committee recommends that all babies in the UK are offered screening for phenylketonuria (PKU), congenital hypothyroidism (CHT), sickle cell disorders (SCD), cystic fibrosis (CF) and medium-chain acyl-CoA dehydrogenase deficiency (MCADD). Identified early enough and with the right medication and follow-up during the early years, the impact of these conditions on the affected children can be greatly reduced or even eliminated. It is therefore vital that tests done on bloodspots indicating the possible presence of any of the conditions during the screening process are acted upon immediately and accurately.

ISS OMNI-Lab installed at Addenbrookes Hospital (UK) Neonatal Laboratory

Press Release


Integrated Software Solutions are pleased to announce that OMNI-Lab has been successfully implemented Live at Addenbrooke's Hospital (ABH) Neonatal Laboratory in the United Kingdom. as an initial trail.


The ABH Neonatal Laboratory had no computerised system before OMNI-Lab, other than manually transposing result data into the main hospital LIS for reporting.


OMNI-Lab interfaces to Child Health Authorities for the region and utilises the current National Screening Result Codes and comments that are held in the database providing immediate access for statistical analysis. All data analysis supports standard ODBC and SQL access, enabling ABH to utilise other statistical tools as well as the in-built Q-Writer ad-hoc reporting tool.


Interfacing to analytical instruments including Blood Spot DBS Card Punches, Autodelfia, Tandem and Variant analysers, is achieved using ISS-AIH, Integrated Software Solution's Analytical Instrument Hub.


OMNI-Lab incorporates a powerful Rules module which is used for automatically determining and adding in-lab repeat tests based upon criteria provided by ABH. The rules also incorporate a fully integrated version of "Rodney's Rules" for evaluation of Cystic Fibrosis (CF) results. This feature is available to other Screening laboratories which can support web services provided by Integrated Software Solutions. The Rules module also provides automatic generation of Recall and follow-up letters, where samples and/or data is insufficient, damaged or unsuitable or where Results are equivocal and require a repeat card collection.


OMNI-Lab also supports manual entry of requests for tests and printed/electronic report output, enabling ABH to easily provide services to laboratories and organisations outside their area.

ISS OMNI-Lab installed at Birmingham Children's Hospital (UK) Neonatal Laboratory

Press Release


Integrated Software Solutions are pleased to announce that OMNI-Lab has been successfully implemented Live At Birmingham Children's Hospital (BCH) Neonatal Laboratory in the United Kingdom.


OMNI-Lab interfaces to 22 Child Health Authorities for the region taking in patient demographic updates and delivering results. Data Take-on incorporated Demographics and Results, going back 23 years to 1985. Results were transformed from several old coding systems into the current National Screening Result Codes and comments and are held in the database providing immediate access for statistical analysis. All data analysis supports standard ODBC and SQL access, enabling BCH to utilise other statistical tools as well as the in-built Q-Writer ad-hoc reporting tool.


Interfacing to analytical instruments including Blood Spot Multipunch, Autodelfia, Tandem and Variant analysers, is achieved using ISS- AIH, Integrated Software Solution's Analytical Instrument Hub.


OMNI-Lab incorporates a powerful Rules module which is used for automatically determining and adding in-lab repeat tests based upon criteria provided by BCH. The rules also incorporate a fully integrated version of "Rodney's Rules" for evaluation of Cystic Fibrosis (CF) results. This feature is available to other Screening laboratories which can support web services provided by Integrated Software Solutions. The Rules module also provides automatic generation of Recall and follow-up letters, where samples and/or data is insufficient,damaged or unsuitable or where Results are equivocal and require a repeat card collection.


OMNI-Lab also supports manual entry of requests for tests and printed/electronic report output, enabling BCH to easily provide services to laboratories and organisations outside their area.